Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Average Price Target from Brokerages

Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $147.50.

Several equities analysts have recently weighed in on the stock. Guggenheim restated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th.

Vaxcyte Stock Down 1.1 %

PCVX stock opened at $73.82 on Friday. The company has a 50-day simple moving average of $81.26 and a 200 day simple moving average of $93.61. The company has a market capitalization of $9.51 billion, a P/E ratio of -16.05 and a beta of 1.02. Vaxcyte has a fifty-two week low of $58.10 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Equities analysts anticipate that Vaxcyte will post -4.21 EPS for the current year.

Insider Buying and Selling

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,472,066.41. This represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,250 shares of company stock worth $3,840,018. Insiders own 3.10% of the company’s stock.

Institutional Trading of Vaxcyte

Several large investors have recently made changes to their positions in the stock. Whipplewood Advisors LLC acquired a new stake in Vaxcyte in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC lifted its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new stake in shares of Vaxcyte during the 4th quarter worth $41,000. Blue Trust Inc. grew its stake in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after acquiring an additional 775 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.